COPA, an Automated Medication Dispensing and Remote Management System for at Home Methadone Dispensing

摘要 美沙酮维持减少和/或消除阿片类药物的使用，降低死亡率 和与阿片类药物使用相关的犯罪行为，并使患者能够改善他们的健康和社交 生产力。此外，参加美沙酮维持治疗(MMT)可以减少 传播与阿片类药物注射有关的传染病，如肝炎和艾滋病毒。 计算机口腔处方管理系统(COPATM)设备正在开发中 作为一种自动口服液分配系统。COPA专门设计用来输送液体 口服受控和非受控药物给经过验证的目标用户。虽然有必要 COPA始于阿片类药物的流行，不良后果在过去的几年中不断升级 二十年来，对支持阿片类药物使用障碍的带回家的设备的需求更加迫切 (OUD)在新冠肺炎大流行开始时出现患者。这场大流行限制了 两个城市的美沙酮维持治疗/阿片类药物治疗方案的获得情况 以及美国的农村地区。COPA设备在家用美沙酮方面有着重要的应用 维护治疗，基于设备对两者的创新双重生物识别确认 在送药前病人的指纹和牙列。我们计划设计、设计和设计 人为因素测试增强型COPA原型，并提交FDA De Novo批准。

ABSTRACT Methadone maintenance reduces and/or eliminates the use of opioids, reduces the death rates and criminality associated with opioid use, and allows patients to improve their health and social productivity. In addition, enrollment in Methadone Maintenance Treatment (MMT) can reduce the transmission of infectious diseases associated with opioid injection, such as hepatitis and HIV. The Computerized Oral Prescription Administration System (COPATM) device is being developed as an automated oral liquid dispensing system. COPA is specifically designed to deliver liquid oral controlled and non-controlled medications to the validated Intended User. While the need for COPA began with an opioid epidemic with adverse consequences that have escalated in the last two decades, an even more urgent need for a take-home device supporting opioid use disorder (OUD) patients emerged at the onset of the COVID-19 pandemic. The pandemic has limited access to methadone maintenance therapy/treatment at opioid treatment programs in both urban and rural sections of the US. The COPA device has a major application to at-home methadone maintenance treatment, based upon the device's innovative dual biometric confirmation of both the patient's fingerprint and dentition before delivery of drug. We propose to design, engineer and human factor test an enhanced COPA prototype and submit it for FDA De Novo approval.